My Verdict on Hims & Hers Stock -- To The Moon?

Рет қаралды 9,548

23 күн бұрын

📈 Check out Finchat for FREE!: finchat.io/brian/
▼FREE ACCOUNTING INFOGRAPHIC EBOOK:▼
🧑‍🎓 Financial Statements School: longtermmindset.co/fssebook
▼ABOUT US:▼
👨‍💼Brian Feroldi is an author (amzn.to/3JVr9Q0), investor, KZfaqr, and financial educator. He's been investing in the stock market since 2004. Brian likes to buy and hold the highest quality companies he can find.
👨‍💼Brian Stoffel is a writer, investor, KZfaqr, and financial educator. He's a teacher at heart. Brian has been investing for over a decade and has written over 4,000 articles for The Motley Fool. Brian plans his life and his investments around “antifragile” principles.
❗️❗️DISCLAIMER:❗️❗️
All content on this channel is for discussion, education, entertainment, and illustrative purposes only and SHOULD NOT be construed as professional financial advice, solicitation, or recommendation to buy or sell any securities, notwithstanding anything stated on this channel. There are risks associated with investing in securities. Loss of principal is possible. Past performance is not a predictor of future investment performance. Brian Feroldi and the guests on this channel are not responsible for investment actions taken by viewers. Should you need such advice, consult a licensed financial advisor, legal advisor, or tax advisor. You agree to verify all information yourself before investing. Any past performance discussed during this program is no guarantee of future results. Investing involves risk and possible loss of principal capital; please seek advice from a licensed professional.
All views expressed are personal opinions as of the date of recording and are subject to change without the responsibility to update views. No guarantee is given regarding the accuracy of the information on this channel. Releasees undertake no obligation to provide accurate or sound investment statements. You waive any and all duties that may exist flowing from you to any Releasee. You agree not to hold any Releasee liable for any possible claim for damages arising from any decision you make based on information or other content on the Channel.
*Some of the links and other products in this video are from companies for which Brian Feroldi will earn an affiliate commission or referral bonus. Brian Feroldi is part of an affiliate network and receives compensation for sending traffic to partner sites. The content in this video is accurate as of the posting date.

Пікірлер: 61

@samuelmandel4537 22 күн бұрын

Fantastic video, please do more videos of you running companies through your checklist. Thank you!

@EarthwithTom 22 күн бұрын

Thank you for bringing back the anti fragile checklist videos. I really enjoy the videos where you run a company through your checklist

@stoffelbrian 22 күн бұрын

Glad you like it

@chatty9573 22 күн бұрын

Absolutely loved this! So helpful to see you run through a company and how you look at the Anti Fragile checklist. Thanks Stoffel!

@andrewhardaway105 21 күн бұрын

Hims and other compounding pharmacies are only allowed to make GLP-1-based medications because the FDA has declared them in shortage. If/when supply and demand normalizes for these drugs, compounding pharmacies will not be able to sell them and these meds will be subject to normal exclusivity rules. GLP-1s should not be a thesis for owning it.

@danee500 22 күн бұрын

Mann I felt like a kid is a candy store when I saw the hims thumbnail. As a fairly new subscriber to your channel I've watched a lot of your videos and I respect your research and analysis. I always hoped you'd do a video on hims and it's finally here!. Hims is by far my largest investment so it's always nice to see a new perspective on the company. With that being said, I think analyst are being way way to conservative on this company’s growth prospects. With the launch of their recent weigh loss solutions and many new products coming in the pipeline, I believe hims will crush these estimates year after year!

@stoffelbrian 22 күн бұрын

Glad you like it. I don't doubt the growth opportunities, but whether or not HIMS will **profitably** grab market share from those opportunities

@nikc5816 22 күн бұрын

Great detail and extremely logical. Waiting for NU Holdings going through AntiFragile Investing Framework!

@bryanmonkhouse5800 22 күн бұрын

This is a terrific video and walkthrough of the theory behind your framework. One way of expressing moats in a reverse DCF is to flex the number of high-growth years in the first phase. EG MSFT moat might be worth 12 elevated years, LULU HIMS, and dare I say NIKE maybe 7 or 8. after all, the purpose of a moat is to make it take longer to storm the castle while we round up allies for the defense

@MoneyMathai 21 күн бұрын

Can you please do a video on AFRM(Affirm)?

@fozziewossie 22 күн бұрын

Great to have the antifragile checklist review back 👍

@golino4593 20 күн бұрын

Great video Brian. Thanks. Waiting your video on SoFi.

@AC-ge2tr 19 күн бұрын

More of such deep dive analysis videos please, Brians! Great value

@AnthonyAsael 16 күн бұрын

it would be good to add the scale of points you give. Sometimes the maximum points are 1, other times 2 and other 3.... so it is sometimes hard to follow when you give points.... Can you specify this ?

@JackOfAllTrades428 22 күн бұрын

$HIMS is one of the most undervalued stocks in Wall Street along with $OLPX and $HNST.

@Jarkkatube 21 күн бұрын

Thanks Brian. I would consider netwok effect (more data to improve precription AI) and low cost production (maybe not the products, but process side) in moat.

@samueljflesch9791 22 күн бұрын

Oh man !! I I really wish to have found out about this channel just before going to the Uni with all the debt I had to. Top-notch valuation.

@randallr71 22 күн бұрын

Great analysis 💪

@MrAfricanpilot 20 күн бұрын

More of these great analysis videos please!

@kevinkostka7768 22 күн бұрын

Selling generic products gives hims pricing power. The risk of legislation or health side effects are common and to be expected with any pharmacy. I think this actually adds to their moat since Amazon may be less willing to align their brand with products that have health risks

@bombmanNL 22 күн бұрын

Great comment and totally agree, those moat concerns are easy to ‘stab’ the stock down but big tech like Amazon will never risk their image for uncertain risks like health. Also, Americans don’t like to give their health data to big tech or the info their genitals aren’t working properly. HIMS has fenomenaal branding and independent/anonymous product shipping. A trusted health partner for every young American, I think

@jacob6478 20 күн бұрын

I agree with everything you guys said here. Will assume moat gets better until proven otherwise.

@atthemomentbaiked 15 күн бұрын

How did u get from 16% to 20% implied growth rate by (what it looks like) merely looking at growth rate of diluted shares outstanding?

@Keithceesau 22 күн бұрын

Great video. Is it easy to create the Reverse discounted cash flow analysis to Excel or are you able to provide a link? Thanks

@fabio2634 21 күн бұрын

Love the new format!!! Thanks for the video!

@jerryhunter5242 22 күн бұрын

Great video. As always.

@sagig72 22 күн бұрын

Great video. If at all possible, can you do PYPL ?

@Floormat212 22 күн бұрын

How are Okta and Docusign doing these days? Could you review those?

@nolanphillips4265 21 күн бұрын

Fantastic video thanks again Brian

@gentleben590 22 күн бұрын

Great review. Great hair.

@jaeyoungchoi6790 22 күн бұрын

maybe you can improve your reverse dcf calculator so that you can input share dilution rate and that is reflected as well? instead of just guessing and adding that 4%

@sharad1878 22 күн бұрын

You’re the man Brian

@platoscavealum902 16 күн бұрын

Thank you

@NASAcoverage 22 күн бұрын

Brian they have a really sweet flywheel also, as the active ingredient in the hair loss medication is finasteride. Which has been know to have a side effect of Erectile Disfunction. Hook em with bald medication keep em coming for the ED meds😅

@sadashidesajib 6 күн бұрын

Thanks for evaluating $HIMS stock. I am a huge fan of this stock.

@crunchycho 22 күн бұрын

interested in hims, but also unconvinced. hard to balance amazing growth potential against what seems to be a unproven moat(s)

@freddiejonesy6168 21 күн бұрын

Great video!

@cw5335 21 күн бұрын

The TAM of sick care is so huge and that allows HIMs maintaining a high growth rate. With zero debt and growing cash, HIMS will start buying back shares. At worst, HIMS will be acquired by Amazon.

@JasonW007 22 күн бұрын

Thank you for doing these again. Your best content imo.

@stockinvest447 22 күн бұрын

What a quality of the video. This is just outstanding. Thank you for that work!

@nickjerrat 22 күн бұрын

great stuff, same reason I didn't invest despite so much encouragement to do so, the moat is weak.

@isaacoliva8889 21 күн бұрын

I’m a hims bull and 0 in debt is incorrect they have 11.2 mil in debt

@tannervolz3035 21 күн бұрын

I'm in at $7 from back in August. At that price almost a no brainer. Not sure I would buy today at this price.

@ahmedalromaih7997 19 күн бұрын

I think quarter by quarter things get more clearer..

@alexkoch14 22 күн бұрын

Big fan of the channel rebrand including the changes to your editing style. Much more professional. Good stuff.

@vikramw 22 күн бұрын

Please make a video on Five9 🙏🏻

@jacob6478 20 күн бұрын

You’re not taking into account the GLP-1 that is offered and going to boost revenue, profitability, moat and free cash flow. Ozempic is a huge deal. Second to generative AI. Look at Eli Lilly. The eatimates for the company are too low. They will be bringing in 3 billion plus for 2026.

@investormd4436 21 күн бұрын

now the antifragile score is biased toward safer blue chip companies like amazon. the valuation in terms of growth is also much harder to be sure for smaller companies like hims where especially for growth, disruptor companies, any growth or death can happen. One big part of upside for the company lies in whether the technology platform can create new demand, kind of like how coke was able to be consumed to an extent that was unanticipated.

@chrisvega5871 22 күн бұрын

Can I give something stronger than a like? Because this is great content Brian. I'll be sharing on X.

@stoffelbrian 22 күн бұрын

Thanks

@tipkoonline 22 күн бұрын

You know your numbers but I think you don't understand the business and where it's headed

@adamsaunders9876 21 күн бұрын

Maybe Amazon could enter this space but they have already said how incredibly hard that would be, but do not underestimate how lazy people are and if popping pills allows you to keep on living a shitty lazy lifestyle and keep you 'healthy' they will rather than make real changes. HIMS is the one stock I have I think could make me actually rich in 10 to 15 years time

@soundslight7754 22 күн бұрын

Great education video. I'm shocked HIMS makes profits, perhaps resonates with the tiktok generation

@danee500 22 күн бұрын

It’s no surprise to me that their making money. so many investors have dismissed this company as an ED company. But if you dig deep you’ll see that they’re so much more. Hims is disrupting the massive healthcare industry, needlessly to say this is a generational buy in my opinion

@amostageer 22 күн бұрын

Hims and hers is a generational buying opportunity. Life altering stock for sure

@jamiemiller6156 22 күн бұрын

It is a company that relies on spending a fortune to push unproven products. I would be very weary of legal liability down the road. I would recommend anyone who gets in this company watch it like a hawk as everything could change extremely rapidly.

@BoltarThePirate 22 күн бұрын

The side effects of the drugs they sell automatically make you a customer of the next drug.. it is quite viscious